irak4

IRAK4-IN-10 (compound 75) is a potent IRAK4 inhibitor (IC50 = 1.5 nM) that can block the MyD88-dependent signaling pathway and has research potential in inflammatory diseases, autoimmune diseases, and cancer.

IRAK4-IN-8 (VI-177) is an IRAK4 inhibitor used to study diseases related to cancer and inflammation.

IRAK4-IN-4 (compound 15) inhibits cyclic GMP-AMP synthase (cGAS) with an IC50 of 2.1 nM.IRAK4-IN-4 is an interleukin-1 receptor–associated kinase 4 (IRAK4) inhibitor, has an IC50 of 2.8 nM.

IRAK4-IN-7 (CA-4948) is a selective and potent IRAK4 kinase inhibitor with in vivo activity in a TLR4-induced cytokine release model.

IRAK4-IN-20 is a potent and orally active IRAK4 inhibitor (IC50:3.55 nM). IRAK4-IN-20, which has anti-inflammatory, antitumor and anticancer effects, is often used to treat acute respiratory distress syndrome (ARDS).

HS271 is a selective, highly potent and orally active IRAK4 inhibitor (IC50= 7.2 μM). HS271 shows excellent enzymatic and cellular activities, as well as excellent pharmacokinetic properties.

Thalidomide 4-fluoride (E3 ligase Ligand 4) (Cereblon ligand 4) is the Thalidomide-based Cereblon ligand. Thalidomide 4-fluoride can be used in the recruitment of CRBN protein. Thalidomide 4-fluoride (Cereblon ligand 4) can be connected to the ligand for IRAK4 protein by a linker to form PROTAC IRAK4 degrader-1.

IRAK4-IN-1 is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with an IC50 of 7 nM.

CA-4948 (Emavusertib) is a potent IRAK4 FLT3 inhibtor. CA-4948 with anti-tumor activity.

Zimlovisertib (PF-06650833) is an effective, selective and orally active inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4) (IC50s: 0.2 and 2.4 nM in the cell and PBMC assay).

IRAK4-IN-6 is a selective and orally efficacious inhibitor of IRAK4, demonstrating an IC50 value of 4 nM. This compound specifically targets MyD88 L265P mutant diffuse large B-cell lymphoma [1].

PROTAC IRAK4 degrader-1 (compound I-210) is a Cereblon based PROTAC consisting of the PROTAC IRAK4 ligand-1, the E3 ligase ligand Pomalidomide and the PROTAC linker AM-Imidazole-PA-Boc.

PROTAC IRAK4 ligand-1 is a synthetic ligand targeting interleukin-1 receptor-associated kinase 4 (IRAK4).

PROTAC IRAK4 degrader-12, a Cereblon ligand-based PROTAC, induces a maximum degradation of IRAK4 in K562 cells at 108.46% with an IC50 value of 4.87 nM. (Structure Note: Pink, IRAK4 Inhibitor; Blue, E3; Black, linker.)

PROTAC IRAK4 ligand-5, a ligand for the target protein of PROTAC, is instrumental in the synthesis of KT-413.

PROTAC IRAK4 ligand-4, a Ligand for Target Protein for PROTAC (Ligand for Target Protein for PROTAC), exhibits anti-tumor activity and is utilized in synthesizing PROTAC IRAK4 degrader-12. This compound serves as a targeted ligand with specific applications in the development of cancer therapeutics.

IRAK4 ligand-12 is a target protein ligand for PROTAC (Ligand for Target Protein for PROTAC) and is utilized in the synthesis of KTX-951.

IRAK4-IN-30 (Compound I) is an inhibitor of IRAK4, with an IC50 of 0.6 nM.

IRAK4ligand-13 is an IRAK4 ligand and serves as a PROTAC target protein ligand. It is utilized in the synthesis of PROTAC compounds, such as LZ-07.

IRAK4-IN-31 is a crystalline inhibitor of IRAK4. It is applicable in research related to myelodysplastic syndromes (MDS).

IRAK4-IN-16 (compound 4) is a potent inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4) with an IC50 of 2.5 nM. It exhibits cytotoxicity against OCI-LY10, TMD8, Ramos, and HT cells, with IC50 values of 0.2, 0.2, 0.6, and 2.7 μM, respectively [1].

PROTAC IRAK4 degrader-4 (US20190192668A1, compound I-127) is a Cereblon-based PROTAC specifically designed to target and degrade interleukin-1 receptor-associated kinase 4 (IRAK4).

PROTAC IRAK4 degrader-5 is a Cereblon-based compound designed to selectively degrade IRAK4.

PROTAC IRAK4 degrader-6 is a potent Cereblon-based compound designed to degrade [interleukin-1 receptor-associated kinase 4 (IRAK4)].